Skip to product information
a transparent glass vial labeled 'CJC with DAC 10 mg, Batch No.002, 15-08-2025.' The vial contains a pale powder, features a gray rubber stopper with a matte metal cap, and sits against a soft beige background with diffused lighting for a clean, professional look
1/2
CJC-1295 with DAC 10mg vial

CJC-1295 with DAC 10mg vial

€50,00 EUR
Taxes included.

                                      NOT FOR HUMAN CONSUMPTION

CJC-1295 with DAC (Drug Affinity Complex) is a stabilized growth-hormone–releasing hormone (GHRH) analogengineered to covalently bind circulating albumin via its DAC moiety. This albumin conjugation dramatically extends systemic residence and sustains physiologic, pulsatile GH release with downstream IGF-1 elevation. In contrast to daily GHRH analogs (e.g., sermorelin) or short-acting “CJC without DAC” (Mod-GRF 1-29), DAC-conjugated CJC enables infrequent injections (weekly to twice-monthly in studies). It is not FDA/EMA-approved for therapeutic use.

Additional Benefits of CJC-1295 with DAC Now Under Investigation

Benefit Key take-aways
1 Long-acting physiologic GH support Single injections amplify GH pulse amplitude and raise IGF-1 for ~1–2 weeks, preserving hypothalamic feedback (somatostatin/IGF-1) rather than delivering non-physiologic GH exposure. <br/><em>Journal of Clinical Endocrinology & Metabolism; Endocrine Reviews</em>
2 Adherence advantage vs daily secretagogues Weekly/bi-weekly regimens improve treatment convenience and may enhance persistence compared with nightly GHRH or multiple daily secretagogue dosing. <br/><em>Clinical Endocrinology; Patient Preference and Adherence</em>
3 Body-composition signals Exploratory studies report reductions in visceral adiposity with maintenance or slight increases in fat-free mass, consistent with GH/IGF-1 physiology. <br/><em>Obesity; JCEM</em>
4 Lipids & inflammatory markers Responders show lower triglycerides and CRP with adiponectin increases, aligning with improved cardiometabolic risk profiles. <br/><em>Journal of Clinical Lipidology; Metabolism</em>
5 Sleep architecture Bedtime administration augments slow-wave sleep (SWS) in midlife adults with blunted nocturnal GH secretion; effects track with IGF-1 rises. <br/><em>Sleep; Neuroendocrinology</em>
6 Bone turnover Short-term increases in bone-formation markers (P1NP, osteocalcin) via GH→IGF-1 routes; fracture outcomes untested. <br/><em>Bone; Osteoporosis International</em>
7 Hepatic steatosis hypothesis By reducing visceral fat and modulating hepatic lipid flux, programs explore MRI-PDFF improvements in NAFLD phenotypes; robust trials are pending. <br/><em>Hepatology; Liver International</em>
8 Synergy with GHSR agonists Additive GH release when combined with ghrelin-mimetics (e.g., GHRP-2, hexarelin) due to distinct receptors (GHRHR vs GHSR-1a). <br/><em>JCEM; Neuroendocrinology</em>
9 Quality-of-life domains Participants often note energy, recovery, and body-image improvements paralleling endocrine changes—patient-reported outcomes remain exploratory. <br/><em>Endocrine Practice; Quality of Life Research</em>

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

CJC-1295 binds GHRH receptors (GHRHR) on pituitary somatotrophs → Gs–adenylate cyclase–cAMP–PKA–CREB→ GH pulse generation. Physiologic feedback via somatostatin/IGF-1 remains intact. DAC-mediated albumin coupling prolongs receptor exposure without continuous GH infusion.

2.2 Down-stream Biology

Pathway Functional outcome Context
GH→GHR–JAK2–STAT5 ↑ IGF-1, ↑ lipolysis, ↑ protein synthesis Liver, adipose, muscle
PI3K–Akt–mTOR (IGF-1) ↑ translation, ↑ fat-free mass Skeletal muscle
AMPK/PPAR cross-talk ↓ de novo lipogenesis; improved VLDL handling Liver
CNS sleep network ↑ SWS and GH coupling Hypothalamus/cortex

3. Pharmacokinetics

  • Absorption: Effective by SC injection; albumin coupling occurs in vivo.

  • Half-life: Apparent t½ ~5–8 days with IGF-1 elevation persisting ~1–2 weeks after a dose (formulation- and cohort-dependent).

  • Distribution: Albumin-bound fraction predominates, limiting renal filtration and extending exposure.

  • Clearance: Proteolysis of peptide–albumin complex; no CYP interactions expected.

  • Dosing paradigm (investigational): Weekly to twice-monthly schedules in early studies to maintain IGF-1 within the age-adjusted normal range.

4. Pre-clinical and Translational Evidence

4.1 Healthy & Overweight Adults

Single and multiple ascending-dose studies demonstrated significant, sustained IGF-1 increases with acceptable short-term tolerability and a low injection frequency compared with daily secretagogues.

4.2 Growth-Hormone Axis Phenotypes

In adults with functional GH insufficiency features (central adiposity, low-normal IGF-1), pilot work shows favorable endocrine and body-composition trends—pivotal trials are lacking.

4.3 Sleep & Neurocognition

In midlife cohorts, SWS augmentation and modest improvements in executive function have been observed with GHRH-based regimens; CJC-DAC data are limited but mechanistically concordant.

4.4 Metabolic Liver Disease

Programs are exploring NAFLD/MASH endpoints (MRI-PDFF, ALT/AST) based on GH-axis biology; confirmatory randomized evidence is still needed.

5. Emerging Clinical Interests

Field Rationale Current status
Sarcopenic obesity Long-acting physiologic GH pulses to reshape body composition Early feasibility
NAFLD/MASH Visceral-fat reduction + hepatic lipid flux modulation Pilot designs
Sleep/SWS decline Restore nocturnal GH coupling with infrequent dosing Proof-of-concept
Endocrine rehabilitation Adjunct in hypothalamic suppression states (post-stress, critical illness) Exploratory

6. Safety and Tolerability

  • Common: Injection-site reactions, edema, arthralgia/myalgia, paresthesia/carpal-tunnel-like symptoms (fluid retention) as IGF-1 rises.

  • Metabolic: Glucose intolerance can emerge in predisposed patients—monitor FPG/HbA1c.

  • Endocrine: Target IGF-1 within age-normal range; excessive, sustained elevation increases adverse-event risk.

  • Rare/observational: Injection-site nodules (albumin binding), transient headache/flushing.

  • Oncology caution: As with any GH/IGF-1–elevating therapy, theoretical mitogenic risk warrants avoidance in active malignancy and vigilance in those with prior cancer.

Comparative safety matrix

Concern CJC-1295 with DAC Sermorelin (GHRH 1–29) MK-677 (oral GHSR agonist)
Dosing burden Weekly–bi-weekly Nightly SC Daily oral
IGF-1 profile Sustained, physiologic-range (if titrated) Transient, smaller Sustained, higher
Appetite effect Neutral Neutral ↑ (ghrelin-like)
Edema/CTS risk Moderate Low–moderate Moderate
Glycaemic drift Possible Low–mild Moderate

7. Regulatory Landscape

  • Approvals: None for therapeutic use in major markets.

  • Availability: Research/compounded channels in some regions; quality/purity not assured outside regulated trials.

  • Sport: Agents that increase GH/IGF-1 are WADA-prohibited.

8. Future Directions

  • Controlled RCTs in sarcopenic obesity and NAFLD/MASH with imaging (MRI-PDFF) and metabolic endpoints.

  • IGF-1-guided titration strategies to balance efficacy and safety while avoiding supraphysiologic exposure.

  • Combination regimens with exercise, nutrition, or incretin-based therapies to enhance cardiometabolic outcomes.

  • Formulation optimization (stability, injection volume) and real-world adherence studies versus daily secretagogues.

Selected References

  • Teichman S.L. et al. CJC-1295, a long-acting GHRH analog, increases GH and IGF-1 in healthy adults.Journal of Clinical Endocrinology & Metabolism.

  • Ionescu M. et al. Pharmacokinetics and pharmacodynamics of DAC-conjugated GHRH analogs. Clinical Endocrinology.

  • Veldhuis J.D., Iranmanesh A. Physiology of GH pulsatility and feedback. Endocrine Reviews.

  • Johannsson G. et al. Body composition and lipid changes with GH-axis modulation. Obesity; JCEM.

  • Van Cauter E., Born J. GHRH and sleep/somnogenic effects. Sleep; Neuroendocrinology.

  • Clemmons D.R. IGF-1 biology and clinical monitoring. JCEM.

  • Chalasani N. et al. NAFLD endpoints and MRI-PDFF in trials. Hepatology; Liver International.

  • Fukuoka H. et al. Secretagogue synergy (GHRH + GHSR agonists). Neuroendocrinology.

  • WADA. Prohibited List 2025 — peptide hormones and growth factors.